Gene therapy for Parkinson's disease

Expert Review of Neurotherapeutics

Volumn 7, Issue 8, 2007, Pages 957-960

  Mochizuki, Hideki ^a  

^a JUNTENDO UNIVERSITY   (Japan)

Author keywords

AADC; GAD; Gene therapy; Neurturin; Parkin; Parkinson's disease

Indexed keywords

4 AMINOBUTYRIC ACID; ALPHA SYNUCLEIN; AROMATIC LEVO AMINO ACID DECARBOXYLASE; AV 201; CERE 120; DOPAMINE; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GLUTAMATE DECARBOXYLASE; GUANOSINE TRIPHOSPHATE CYCLOHYDROLASE I; LEVODOPA; NEURTURIN; NLXP 101; PARKIN; PARVOVIRUS VECTOR; TYROSINE; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG;

ARTICLE; AUTOSOMAL RECESSIVE INHERITANCE; CLINICAL TRIAL; CORPUS STRIATUM; GENE EXPRESSION; GENE LOCUS; GENE MUTATION; GENE REPLACEMENT THERAPY; GENE THERAPY; GENE TRANSFER; HUMAN; NONHUMAN; PARKINSON DISEASE; SUBTHALAMIC NUCLEUS;

ANIMALS; GENE THERAPY; HUMANS; PARKINSON DISEASE;

EID: 34548036477     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.7.8.957     Document Type: Article

References (37)

1. Mochizuki H, Mizuno Y. Gene therapy for Parkinson's disease. J. Neural Transm. Suppl. 65, 205-213 (2003).
2. von Bohlen Und Halbach O. Modeling neurodegenerative diseases in vivo review. Neurodegener. Dis. 2(6), 313-320 (2005).
3. Mochizuki H, Yamada M, Mizuno Y. α-synuclein overexpression model. J. Neural Transm. Suppl. 70, 281-284 (2006).
4. Nagatsu T, Yamaguchi T, Rahman MK et al. Catecholamine-related enzymes and the biopterin cofactor in Parkinson's disease and related extrapyramidal diseases. Adv. Neurol. 40, 467-473 (1984).
5. Kaplitt MG, Leone P, Samulski RJ et al. Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain. Nat. Genet. 8(2), 148-154 (1994). •• Landmark study on adeno-associated virus (AAV) vector-based gene therapy for Parkinson's disease (PD).
6. Shen Y, Muramatsu SI, Ikeguchi K et al. Triple transduction with adeno-associated virus vectors expressing tyrosine hydroxylase, aromatic-L -amino-acid decarboxylase, and GTP cyclohydrolase I for gene therapy of Parkinson's disease. Hum. Gene Ther. 11(11), 1509-1519 (2000).
7. Lo WD, Qu G, Sferra TJ, Clark R, Chen R, Johnson PR. Adeno-associated virus-mediated gene transfer to the brain: duration and modulation of expression. Hum. Gene Ther. 10(2), 201-213 (1999).
8. Sanftner LM, Rivera VM, Suzuki BM et al. Dimerizer regulation of AADC expression and behavioral response in AAV-transduced 6-OHDA lesioned rats. Mol. Ther. 13(1), 167-174 (2006).
9. Bankiewicz KS, Forsayeth J, Eberling JL et al. Long-term clinical improvement in MPTP-lesioned primates after gene therapy with AAV-hAADC. Mol. Ther. 14(4), 564-570 (2006).
10. Guridi J, Luquin MR, Herrero MT, Obeso JA. The subthalamic nucleus: a possible target for stereotaxic surgery in Parkinson's disease. Mov. Disord. 8(4), 421-429 (1993).
11. Bergman H, Wichmann T, DeLong MR. Reversal of experimental parkinsonism by lesions of the subthalamic nucleus. Science 249(4975), 1436-1438 (1990).
12. Alexander GE, Crutcher MD. Functional architecture of basal ganglia circuits: neural substrates of parallel processing. Trends Neurosci. 13(7), 266-271 (1990).
13. Luo J, Kaplitt MG, Fitzsimons HL et al. Subthalamic GAD gene therapy in a Parkinson's disease rat model. Science 298(5592), 425-429 (2002). •• Landmark study on AAV vector-based GAD gene therapy for PD.
14. Lin LF, Doherty DH, Lile JD, Bektesh S, Collins F. GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science 260(5111), 1130-1132 (1993).
15. Mandel RJ, Spratt SK, Snyder RO, Leff SE. Midbrain injection of recombinant adeno-associated virus encoding rat glial cell line-derived neurotrophic factor protects nigral neurons in a progressive 6-hydroxydopamine-induced degeneration model of Parkinson's disease in rats. Proc. Natl Acad. Sci. USA 94(25), 14083-14088 (1997).
16. Eslamboli A, Georgievska B, Ridley RM et al. Continuous low-level glial cell line-derived neurotrophic factor delivery using recombinant adeno-associated viral vectors provides neuroprotection and induces behavioral recovery in a primate model of Parkinson's disease. J. Neurosci. 25(4), 769-777 (2005).
17. Choi-Lundberg DL, Lin Q, Chang YN et al. Dopaminergic neurons protected from degeneration by GDNF gene therapy. Science 275, 838-841 (1997).
18. Kitada T, Asakawa S, Hattori N et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392(6676), 605-608 (1998).
19. Shimura H, Hattori N, Kubo S et al. Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat. Genet. 25(3), 302-305 (2000).
20. Tanaka K, Suzuki T, Chiba T, Shimura H, Hattori N, Mizuno Y. Parkin is linked to the ubiquitin pathway. J. Mol. Med. 79(9), 482-494 (2001).
21. Imai Y, Soda M, Hatakeyama S et al. CHIP is associated with Parkin, a gene responsible for familial Parkinson's disease, and enhances its ubiquitin ligase activity. Mol. Cell 10(1), 55-67 (2002).
22. Darios F, Corti O, Lucking CB et al. Parkin prevents mitochondrial swelling and cytochrome c release in mitochondria-dependent cell death. Hum. Mol. Genet. 12(5), 517-526 (2003).
23. Higashi Y, Asanuma M, Miyazaki I, Hattori N, Mizuno Y, Ogawa N. Parkin attenuates manganese-induced dopaminergic cell death. J. Neurochem. 89(6), 1490-1497 (2004).
24. Jiang H, Ren Y, Zhao J, Feng J. Parkin protects human dopaminergic neuroblastoma cells against dopamine-induced apoptosis. Hum. Mol. Genet. 13(16), 1745-1754 (2004).
25. Oluwatosin-Chigbu Y, Robbins A, Scott CW, Arriza JL, Reid JD, Zysk JR. Parkin suppresses wild-type α-synuclein-induced toxicity in SHSY-5Y cells. Biochem. Biophys. Res. Commun. 309(3), 679-684 (2003).
26. Petrucelli L, O'Farrell C, Lockhart PJ et al. Parkin protects against the toxicity associated with mutant α-synuclein: proteasome dysfunction selectively affects catecholaminergic neurons. Neuron 36(6), 1007-1019 (2002).
27. Palacino JJ, Sagi D, Goldberg MS et al. Mitochondrial dysfunction and oxidative damage in parkin-deficient mice. J. Biol. Chem. 279(18), 18614-18622 (2004).
28. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. α-synuclein in Lewy bodies. Nature 388(6645), 839-840 (1997).
29. Singleton AB, Farrer M, Johnson J et al. α-synuclein locus triplication causes Parkinson's disease. Science 302(5646), 841 (2003).
30. Yamada M, Mizuno Y, Mochizuki H. Parkin gene therapy for α-synucleinopathy: a rat model of Parkinson's disease. Hum. Gene Ther. 16(2), 262-270 (2005).
31. Lo Bianco C, Schneider BL, Bauer M et al. Lentiviral vector delivery of parkin prevents dopaminergic degeneration in an α-synuclein rat model of Parkinson's disease. Proc. Natl Acad. Sci. USA 101(50), 17510-17515 (2004). • Landmark study on AAV vector-based parkin gene therapy for autosomal recessive juvenile parkinsonism.
32. Vercammen L, Van der Perren A, Vaudano E et al. Parkin protects against neurotoxicity in the 6-hydroxydopamine rat model for Parkinson's disease. Mol. Ther. 14(5), 716-723 (2006).
33. Avigen announces encouraging early data from Parkinson's disease clinical trial (Accessed July 2005) www.avigen.com/non_financial_release/2005/ 2005_Avigen_EarlyData_PDClinicalTrial_071805.htm
34. Genzyme acquires Avigen's gene therapy technology (Accessed December 2005) www.genzyme.com/corp/media/GENZ%20PR-122105.asp
35. Grady D, Kolata G. Gene therapy used to treat patient with Parkinson's. New York Times (Accessed June 2007) http://query.nytimes.com/gst/fullpage.html? sec=health&res=9400EED61030F93AA2575BC0A9659C8B63
36. Neurologix announces positive results of gene therapy clinical trial in Parkinson's disease (Accessed September 2005) www.eurekalert.org/pub_releases/ 2005-09/bm-nap092305.php
37. Ceregene announces positive results of gene therapy clnical traila in Parkinson's disease. www.ceregene.com/Science_parkinsons.asp